SEC Form 4 · accession 0000899243-17-013254
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E. Hughes
Officer — President and CEO · Director
Period of report
May 11, 2017
Accepted (ET)
May 15, 2017 · 8:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2017 | M | 18,928 | $0.75 | A | 83,088 | D | |
| Common StockF1 | May 11, 2017 | M | 6,210 | $0.75 | A | 89,298 | D | |
| Common StockF1 | May 11, 2017 | M | 68,073 | $0.82 | A | 157,371 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to BuyF2 | $0.75 | May 11, 2017 | M | 18,928 | D | — | Dec 15, 2018 | Common Stock | 18,928 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.75 | May 11, 2017 | M | 6,210 | D | — | Mar 18, 2019 | Common Stock | 6,210 | 0 | D |
| Stock Option (Right to Buy)F2 | $0.82 | May 11, 2017 | M | 68,073 | D | — | Mar 10, 2020 | Common Stock | 68,073 | 0 | D |
Explanation of responses
- F1Includes 224 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan on January 1, 2017.
- F2Fully vested.